Details for Patent: 12,295,953

Which drugs does patent 12,295,953 protect, and when does it expire?

Patent 12,295,953 protects BRYNOVIN and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 12,295,953

Title:	Oral gliptin compositions and method for preparation thereof
Abstract:	Described herein are liquid oral gliptin compositions. The liquid oral gliptin compositions may comprise a gliptin or a pharmaceutically acceptable salt thereof, an artificial non-sugar alcohol sweetening agent, and liquid oral gliptin compositions may have a sugar alcohol content of less 25 w/v %. The liquid oral gliptin compositions described herein have improved taste and stability. Further provided herein are methods of manufacturing liquid oral gliptin compositions.
Inventor(s):	Ioannis Psarrakis, Konstantinos Lioumis
Assignee:	Pharma Data Research And Development Single Member SA
Application Number:	US18/587,175
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 12,295,953

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	BRYNOVIN	sitagliptin hydrochloride	SOLUTION;ORAL	219122-001	Jan 16, 2025		RX	Yes	Yes			Y

International Family Members for US Patent 12,295,953

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3811930
European Patent Office	4048230
Spain	2961549
Poland	4048230
World Intellectual Property Organization (WIPO)	2021078964